About Us

Professional company for 3D cell culture platform specialized in anticancer drug sensitivity and efficacy/toxicity test.

Paper 2022, International Journal of Molecular Sciences, Patient-Derived Tum…

Page Info

Author MBD
Comment 0 View 806 Date 23-05-22 15:06


 An obstacle to effective uniform treatment of glioblastoma, especially at recurrence, is genetic and cellular intertumoral heterogeneity.
Hence, personalized strategies are necessary, as are means to stratify potential targeted therapies in a clinically relevant timeframe.
Functional profiling of drug candidates against patient-derived glioblastoma organoids (PD-GBO) holds promise as an empirical method to preclinically discover potentially effective treatments of individual tumors.
Here, we describe our establishment of a PDGBO-based functional profiling platform and the results of its application to four patient tumors.
We show that our PD-GBO model system preserves key features of individual patient glioblastomas in vivo.
As proof of concept, we tested a panel of 41 FDA-approved drugs and were able to identify potential treatment options for three out of four patients; the turnaround from tumor resection to discovery of treatment option was 13, 14, and 15 days, respectively.
These results demonstrate that this approach is a complement and, potentially, an alternative to current molecular profiling efforts in the pursuit of effective personalized treatment discovery in a clinically relevant time period.
Furthermore, these results warrant the use of PD-GBO platforms for preclinical identification of new drugs against defined morphological glioblastoma features.